Advocacy intelligence hub — real-time data for patient organizations
Neveen Abd El Maksoad Kohaf — NA
Kun-Ta Chou
Universitaire Ziekenhuizen KU Leuven — PHASE4
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
ILARIS
(canakinumab)Orphan drugstandardNovartis Pharmaceuticals Corporation
12.1 Mechanism of Action Canakinumab is a human monoclonal anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutr...
Browse all Tumor necrosis factor receptor 1 associated periodic syndrome news →
View all Tumor necrosis factor receptor 1 associated periodic syndrome specialists →